<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138241</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 114</org_study_id>
    <nct_id>NCT01138241</nct_id>
  </id_info>
  <brief_title>Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation</brief_title>
  <official_title>Incidence and Predictor of TDF Associated Nephrotoxicity and Pharmacokinetic of TDF in HIV-1 Infected Thai Patients: A Sub-study of HIV-NAT 006 Long Term Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess and validate equation eGFR in HIV-infected subjects and -uninfected Thai patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With significant reductions in mortality and risk of progression to AIDS with antiretroviral
      therapy (ART), complications of long-standing HIV infection and treatment, including renal
      disease, have become increasingly important. Aging, concomitant metabolic diseases, and use
      of potentially nephrotoxic ART lead to higher risk for renal disease in HIV-infected
      persons.WHO encourage TDF as first line ARV regimen. The data on TDF related renal toxicity
      in Asian population is limited.

      For this cohort, we plan to look at these topics:

        1. proximal tubular dysfunction between TDF and non-TDF user

        2. incidence and predictor of TDF related renal toxicity

        3. TDF plasma concentrations

        4. Pharmacokinetic of TDF when used with boosted DRV, boosted ATV, and boosted LPV in Thai
           population

        5. Bone density and vitamin D in patients with and without hypophosphatemia.

        6. Pharmacogenomic of TDF in Thai population
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to validate eGFR Thai equation in HIV-infected adults</measure>
    <time_frame>Blood specimens were drawn to assess plasma radioactivity at 5, 10, 20, 30, 60, 90, 120, 180, and 240 minutes post 99mTc-DTPA injection</time_frame>
    <description>Test of diagnostic accuracy</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">700</enrollment>
  <condition>Renal Function</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>ARV experience (TDF based HAART)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>ARV experience (non TDF based ART)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>ARV Naive</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tc99mDTPA renal clearance</intervention_name>
    <description>Tc99mDTPA renal clearance only for 200 patients
Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ÃŸ2- microglobulinuria
serum creatinine prior and during TDF
TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels
stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)
serum for cystanin C ( stored sample prior taking ARV and present time)
intensive 24 hours pharmacokinetic study of TDF in 20 patients</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-NAT 006 participants (TDF +non TDF)and ARV naive population

        For TDF group, on TDF &gt; 3 months HIV/HBV co-infected patients from COLD (Liver disease and
        HIV/HBV coinfection in the era of HAART) and TDF surveillance study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt; 18 years old.

          2. HIV RNA &lt; 50 copies/ml (For ART-experienced group only).

        Exclusion Criteria:

          1. a history of Tc-99m DTPA allergy,

          2. malnutrition (BMI &lt;18m2),

          3. amputation,

          4. bed-ridden,

          5. currently taking cotrimoxazole or cimetidine,

          6. acute deterioration of renal function within the last 3 months,

          7. serum creatinine &gt; 1.5 mg/dl, or

          8. pregnant/lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Praphan Phanuphak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kearkiat Praditpornsilpa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renal division, Faculty of Medicine, Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <results_reference>
    <citation>Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, Chaiyahong P, Wongsabut J, Ubolyam S, Chulakadabba A, Avihingsanon Y, Ruxrungtham K, Tunsanga K, Eiam-Ong S, Phanuphak P. Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients. AIDS. 2012 Sep 10;26(14):1781-8. doi: 10.1097/QAD.0b013e328356480d. Erratum in: AIDS. 2013 Mar 13;27(5):853.</citation>
    <PMID>22713478</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Glomerular Filtration Rate (GFR)</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Serum creatinine (sCr)</keyword>
  <keyword>24 hr urine creatinine clearance</keyword>
  <keyword>Serum Cystatin C[40]</keyword>
  <keyword>Modification of Diet in Renal Disease (MDRD)</keyword>
  <keyword>Cockcroft Gault Equation</keyword>
  <keyword>Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)</keyword>
  <keyword>99mTc-diethylenetriaminepentaacetic acid (Tc-99m DTPA) scan</keyword>
  <keyword>Validate which renal function assessments can accurately detect GFR and assess the effect of TDF concentration on renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

